Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors
Summary
This phase I trial tests the safety, side effects, and best dose of ex vivo expanded natural killer cells in treating patients with cancerous (malignant) tumors affecting the upper part of the brain (supratentorial) that have come back (recurrent) or that are growing, spreading, or getting worse (progressive). Natural killer (NK) cells are immune cells that recognize and get rid of abnormal cells in the body, including tumor cells and cells infected by viruses. NK cells have been shown to kill different types of cancer, including brain tumors in laboratory settings. Giving NK cells from unrelated donors who are screened for optimal cell qualities and determined to be safe and healthy may be effective in treating supratentorial malignant brain tumors in children and young adults.
Timeline
- Start
- 2024-05-31
- Primary completion
- 2027-12-31
- Completion
- 2027-12-31
Outcome
Outcome not reported
Stopped (Enrollment): “Enrollment on hold while reviewing a SAE.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells | Cell therapy | 3e+06 cells | Other |
| Subject | Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells | Cell therapy | 3e+07 cells | Other |
| Subject | Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells | Cell therapy | 3e+08 cells | Other |